In a presentation at a New Mexico Support group, Fabio Almeida, MD. gives an overview of the C11 Acetate PET/CT Scan.
View his entire 35 minute presentation here: http://youtu.be/rUbY1aTNZKQ
Also referenced is an article published in the December UroToday regarding some of the C11-Acetate work written by Fabio Almeida, M.D. and co-authored by Mark Scholz, MD. and Richard Lam, MD. This is provided as an open access article to be easily accessible without having to have a subscription to the UIJ.
In brief summary, we did a formal comparison at the Arizona Molecular Imaging Center of multiple time point C11-Acetate PET/CT imaging and found that early imaging was superior to later imaging for areas of metastatic disease (peri-prostate, nodes and bone). We also reviewed our detection rates for finding recurrent cancer in patients with PSA relapse, using early imaging in the larger group of patients we have studied thus far (300). Interestingly, when we compared to other studies from Europe and the US, accounting for the timing of imaging and mean PSA, those studies with early imaging performed better than studies where longer time to imaging was employed – further confirming our findings, with C11-Acetate showing consistent high overall detection rates (82-85%) in this context. Our comparison to C11-Choline detection rates are also showing C11-Acetate to be generally superior, particularly in the low PSA ranges – which means that C11-Acetate is able to find the area(s) of recurrence much earlier.